MenB-FHbp Vaccine Recommendation

Version 14.19

Overview

The information on this page will discuss forecasting and recalls based on when the 2nd dose of MenB-FHbp vaccine was given in compliance with ACIP guidelines. 

Note: There are two MenB vaccines that are licensed in the United States: MenB-FHbp and MenB-4C. This article addresses MenB-FHbp . Recommendations regarding use of MenB-4C (Bexsero) are unchanged.

ACIP Recommendations

These recommendations are regarding use of the 2 and 3 dose schedules of MenB-FHbp vaccine (Trumenba):

Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease (Category A Recommendation)

For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-FHbp should be administered at 0 months, 1–2 months, and 6 months to provide earlier protection and maximize short-term immunogenicity. 

Note: If the second dose of the  MenB-FHbp vaccine is administered six months or later after the first dose was administered, then a third dose should not be administered to the patient.

Adolescents and Young Adults Aged 16–23 Years (Category B Recommendation)

When given to healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months. 

Note: If a second dose of the  MenB-FHbp vaccine is administered earlier than six months after the first dose was administered, then a third dose should be administered at least four months after the second dose.

Dosage and Administration

  • For intramuscular use only 
  • Three-dose schedule: Administer a dose (0.5 mL) at 0, 1-2, and 6 months. 
  • Two-dose schedule: Administer a dose (0.5 mL) at 0 and 6 months. If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose. 
  • The choice of dosing schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal serogroup B disease.

How the Series will Register in the OP Software

The series will be marked complete in the OP software after the two or three doses of MenB-FHbp vaccine are administered to the patient based on the specified period mentioned in the guidelines above.

Resources

Version 14.10

Overview

The information on this page will discuss forecasting and recalls based on when the 2nd dose of MenB-FHbp vaccine was given in compliance with ACIP guidelines. 

Note: There are two MenB vaccines that are licensed in the United States: MenB-FHbp and MenB-4C. This article addresses MenB-FHbp . Recommendations regarding use of MenB-4C (Bexsero) are unchanged.

ACIP Recommendations

These recommendations are regarding use of the 2 and 3 dose schedules of MenB-FHbp vaccine (Trumenba):

Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease (Category A Recommendation)

For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-FHbp should be administered at 0 months, 1–2 months, and 6 months to provide earlier protection and maximize short-term immunogenicity. 

Note: If the second dose of the  MenB-FHbp vaccine is administered six months or later after the first dose was administered, then a third dose should not be administered to the patient.

Adolescents and Young Adults Aged 16–23 Years (Category B Recommendation)

When given to healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months. 

Note: If a second dose of the  MenB-FHbp vaccine is administered earlier than six months after the first dose was administered, then a third dose should be administered at least four months after the second dose.

Dosage and Administration

  • For intramuscular use only 
  • Three-dose schedule: Administer a dose (0.5 mL) at 0, 1-2, and 6 months. 
  • Two-dose schedule: Administer a dose (0.5 mL) at 0 and 6 months. If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose. 
  • The choice of dosing schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal serogroup B disease.

How the Series will Register in the OP Software

The series will be marked complete in the OP software after the two or three doses of MenB-FHbp vaccine are administered to the patient based on the specified period mentioned in the guidelines above.

Resources

Version 14.8

There is no change to version 14.8. We recommend you still follow the guidelines indicated in tab 14.9.